Search - tctmd.com

Displaying 901 - 920 of 1179

Sort: Relevancy | Date

News Daily News

Transradial Approach May Balance Bleeding Benefits of Bivalirudin in Primary PCI

January 15, 2014

News Daily News

El Abordaje Transradial podría Equilibrar los Beneficios Hemorrágicos de la Bivalirudina en las PCI Primarias

January 15, 2014

News Daily News

Primary PCI Reduces Symptoms vs. Fibrinolysis 5 Years after STEMI

January 01, 2014

News Daily News

La PCI Primaria Reduce los Síntomas frente a la Fibrinolisis 5 Años después de un Cuadro de STEMI

January 01, 2014

News Daily News

Statins Reduce Amputations After Lower Extremity Procedures

December 30, 2013

News Daily News

Las Estatinas Reducen las Amputaciones tras Intervenciones en Extremidades Inferiores

December 30, 2013

Transport to Primary PCI vs. On-site Fibrinolysis Is Independent Predictor of Functional Status after MI

Presentation

Transport to Primary PCI vs. On-site Fibrinolysis Is Independent Predictor of Functional Status after MI

Presenter: D.M. Bilkova

December 16, 2013

News Daily News

Bivalirudin Lowers Post-PCI Bleeding Risk Across All Renal Dysfunction Categories

December 10, 2013

Is Gender a Risk Factor? Incidence and Impact of Dual Antiplatelet Therapy (DAPT) Cessation on Adverse Events following Percutaneous Coronary Intervention (PCI): Results from the Real-World PARIS Reg

Presentation

Is Gender a Risk Factor? Incidence and Impact of Dual Antiplatelet Therapy (DAPT) Cessation on Adverse Events following Percutaneous Coronary Intervention (PCI): Results from the Real-World PARIS Reg

Presenter: Roxana Mehran

December 01, 2013

Combining Anticoagulant and Antiplatelet Treatment in Patients with Atrial Fibrillation Undergoing PCI - How to Minimize Bleeding and Ischemic Risks?

Presentation

Combining Anticoagulant and Antiplatelet Treatment in Patients with Atrial Fibrillation Undergoing PCI - How to Minimize Bleeding and Ischemic Risks?

Presenter: Eli Lev

December 01, 2013

News Daily News

HORIZONS-AMI: Mortality Reduction with Bivalirudin Only Partially Due to Bleeding

November 01, 2013

News Daily News

HORIZONS-AMI：使用比伐卢定减少出血仅为死亡率降低的部分原因

November 01, 2013

Potential for Rivaroxaban Use in ACS and in the PCI Patient: Why Different Interpretations of the Same Data in the US and Europe?

Presentation TCT 2013

Potential for Rivaroxaban Use in ACS and in the PCI Patient: Why Different Interpretations of the Same Data in the US and Europe?

Presenter: C. Michael Gibson

October 31, 2013

ARCTIC-INTERRUPTION: A Prospective, Randomized Trial of Two Years vs. One Year of Dual Antiplatelet Therapy After PCI

Presentation TCT 2013

ARCTIC-INTERRUPTION: A Prospective, Randomized Trial of Two Years vs. One Year of Dual Antiplatelet Therapy After PCI

Presenter: Jean-Philippe Collet

October 31, 2013

Risk Stratified Antithrombin Therapy Before and During PCI: State-of-the-Art

Presentation TCT 2013

Risk Stratified Antithrombin Therapy Before and During PCI: State-of-the-Art

Presenter: E. Magnus Ohman

October 31, 2013

Risk Stratified Antiplatelet Therapy in ACS and During PCI: State-of-the-Art

Presentation TCT 2013

Risk Stratified Antiplatelet Therapy in ACS and During PCI: State-of-the-Art

Presenter: Harvey White

October 31, 2013

Prasugrel for PCI in ACS and Stable CAD in Japan: PRASFIT-ACS and PRASFIT-Elective

Presentation TCT 2013

Prasugrel for PCI in ACS and Stable CAD in Japan: PRASFIT-ACS and PRASFIT-Elective

Presenter: Masato Nakamura

October 31, 2013

OPTIMIZE and ARTIC-INTERRUPTION: Perspectives on DAPT Duration after PCI

Presentation TCT 2013

OPTIMIZE and ARTIC-INTERRUPTION: Perspectives on DAPT Duration after PCI

Presenter: Peter Wenaweser

October 31, 2013

GIANT: A Prospective Registry Study of CYP2C19 Genetic Profiling for Thienopyridine Management After Primary PCI in Acute Myocardial Infarction

Presentation TCT 2013

GIANT: A Prospective Registry Study of CYP2C19 Genetic Profiling for Thienopyridine Management After Primary PCI in Acute Myocardial Infarction

Presenter: Bernard Chevalier

October 31, 2013

Featured Trial of the Day: OPTIMIZE: A Prospective, Randomized Trial of Three Months vs. 12 Months of Dual Antiplatelet Therapy After PCI

Presentation TCT 2013

Featured Trial of the Day: OPTIMIZE: A Prospective, Randomized Trial of Three Months vs. 12 Months of Dual Antiplatelet Therapy After PCI

Presenter: Fausto Feres

October 31, 2013

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.